Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1265 (LINC01265), also referred to as OSMR divergent transcript (OSMR-DT), is a member of the lncRNA class located in an antisense orientation relative to the OSMR gene. Divergent lncRNAs like OSMR-DT are transcribed from promoter regions opposite to neighboring protein-coding genes, and are increasingly recognized for their possible roles in local chromatin regulation, gene expression modulation in cis, and perhaps broader transcriptomic regulation. They tend to have more complex promoter structure and higher expression than other intergenic lncRNAs, but the functions of most, including OSMR-DT, are not fully elucidated[3][4]. There are no approved drugs or established mechanisms of action related to OSMR-DT, nor is it considered a classical therapeutic target. Its alias list is consistent with contemporary genome databases and lncRNA nomenclature[1].
Not applicable (lncRNA, no direct drugs or small molecules known to interact)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1265 (LINC01265).